Association of baseline EASIX with progression-free survival in patients with HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors
Frontiers in Oncology · 20.11.2026 · 16
DOI: 10.3389/fonc.2026.1951409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Emre Özge und 1 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Baseline prognostic biomarkers may help characterize heterogeneous outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer. We examined the association between the Endothelial Activation and Stress Index (EASIX) and progression-free survival (PFS) during first-line CDK4/6 inhibitor plus endocrine therapy.
Methods
This retrospective single-center cohort included 108 patients. EASIX was evaluated primarily as standardized log10(EASIX) in Cox regression, with adjustment for age, de novo metastatic disease, liver metastasis, and CDK4/6 inhibitor type. Ridge-penalized models were sensitivity analyses. Cumulative/dynamic time-dependent ROC analyses evaluated discrimination at 12 and 24 months. Cut-off-based analyses were exploratory.
Results
There were 63 PFS events. Median follow-up by reverse Kaplan–Meier was 25.9 months (95% CI, 20.0–27.0). Each one-standard-deviation increase in log10(EASIX) was associated with shorter PFS in the univariable model (HR, 2.11; 95% CI, 1.57–2.82; p < 0.001) and adjusted model (HR, 2.18; 95% CI, 1.61–2.94; p < 0.001). EASIX AUCs were 0.709 (95% CI, 0.598–0.816) at 12 months and 0.742 (95% CI, 0.619–0.854) at 24 months. AUC estimates were numerically higher than those of the individual components. Using the exploratory raw EASIX threshold of 1.20, median PFS was 36.0 months in the low group and 12.0 months in the high group.
Conclusions
Higher baseline EASIX was associated with shorter PFS. These findings support further evaluation of EASIX, but do not establish clinical utility, an endothelial-specific mechanism, or a validated treatment threshold. External validation is required.
Zitieren
APA
Özge, E., & Gürsu, R. U. (2026). Association of baseline EASIX with progression-free survival in patients with HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1951409
Vancouver
Özge E, Gürsu RU. Association of baseline EASIX with progression-free survival in patients with HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1951409
BibTeX
@article{zge2026,
author = {Özge, Emre and Gürsu, Rıza Umar},
title = {Association of baseline EASIX with progression-free survival in patients with HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1951409}
}
EUVIMED